SCHEMBL3099469

SCHEMBL3099469

NC(=O)N1C=CSN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28207250 0.98
SCHEMBL1040037 0.78
SCHEMBL18282566 0.67
SCHEMBL7060720 0.67
SCHEMBL27762376 0.64
SCHEMBL7057853 0.59
SCHEMBL8671099 0.57
SCHEMBL159809 0.57
Urea SCHEMBL8582182 0.49
Carbamic Acid SCHEMBL7761081 0.46

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9580438-B2 Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders 4SC DISCOVERY GMBH (DE) 2017-02-28 US claimed
EP-2903985-A1 SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF Advinus Therapeutics Limited (IN) 2015-08-12 EP claimed
WO-2014054053-A1 SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF ADVINUS THERAPEUTICS LIMITED (IN) 2014-04-10 WO claimed
WO-2005092304-A2 ANTIFUNGAL AGENTS F2G LTD (GB) 2005-10-06 WO claimed
CN-120271532-A 1,2, 3-Thiadiazole amide derivative containing oxime ether unit, and preparation method and application thereof 江苏海洋大学 2025-07-08 CN disclosed
WO-2023059582-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2023-04-13 WO disclosed
EP-3774782-A2 ATF6 INHIBITORS AND USES THEREOF Black Belt TX Ltd (GB) 2021-02-17 EP disclosed
WO-2020211822-A1 A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF 成都海创药业有限公司 2020-10-22 WO disclosed
EP-3414239-A2 INHIBITORS OF RECEPTOR-INTERACTING PROTEIN KINASE 1 Denali Therapeutics Inc. (US) 2018-12-19 EP disclosed
WO-2017136727-A2 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2017-08-10 WO disclosed
CN-103626720-B Mitotic kinesin inhibitors and using method thereof 阿雷生物药品公司 2016-11-16 CN disclosed
EP-2903985-A1 SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF Advinus Therapeutics Limited (IN) 2015-08-12 EP disclosed
EP-2099793-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE Merck Frosst Canada Ltd. (CA) 2009-09-16 EP disclosed
WO-2009100171-A1 FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-13 WO disclosed
WO-2008128335-A1 NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2008-10-30 WO disclosed
WO-2008064474-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2008-06-05 WO disclosed
EP-1114167-A1 SALICYLIC ACID INDUCIBLE GENES AND PROMOTERS FROM TOBACCO Syngenta Mogen B.V. (NL) 2001-07-11 EP disclosed
WO-2000008186-A1 NEW SALICYLIC ACID INDUCIBLE GENES AND PROMOTERS FROM TOBACCO MOGEN INTERNATIONAL NV (NL) 2000-02-17 WO disclosed
EP-0773930-A1 AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS ZENECA LIMITED (GB) 1997-05-21 EP disclosed
CN-1134936-A Herbicidal (1,2,4) thiadiazoles AMERICAN CYANAMID CO (US) 1996-11-06 CN disclosed